Literature DB >> 8384254

Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme.

J M Rozental1, J D Cohen, M P Mehta, R L Levine, J M Hanson, R J Nickles.   

Abstract

Sequential positron emission tomographic scans with [18F]-2-fluorodeoxyglucose (PET-FDG) were performed on 6 patients with glioblastoma multiforme who were treated with adjuvant BCNU. Scans were acquired before and 24 hours after BCNU. All patients had prior brain irradiation. Ratios between the maximal tumor FDG uptake and the contralateral white matter FDG uptake, the glucose uptake ratio, were determined. Percent changes in the glucose uptake ratio between the baseline scan and the 24 hour post-treatment scan were of prognostic significance. Patients with the largest percent changes in FDG uptake had the shortest survival. In contrast, neither the baseline glucose uptake ratio nor the visual tumor grade accurately predicted length of survival.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384254     DOI: 10.1007/bf01050264

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Cerebral diaschisis in patients with malignant glioma.

Authors:  J M Rozental; R L Levine; R J Nickles; J A Dobkin; J M Hanson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

2.  PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.

Authors:  P E Valk; T F Budinger; V A Levin; P Silver; P H Gutin; W K Doyle
Journal:  J Neurosurg       Date:  1988-12       Impact factor: 5.115

3.  Depressed cerebellar glucose metabolism in supratentorial tumors.

Authors:  N J Patronas; G Di Chiro; B H Smith; R De La Paz; R A Brooks; H L Milam; P L Kornblith; D Bairamian; L Mansi
Journal:  Brain Res       Date:  1984-01-16       Impact factor: 3.252

4.  Contralateral cerebellar hypometabolism following cerebral insult: a positron emission tomographic study.

Authors:  M Kushner; A Alavi; M Reivich; R Dann; A Burke; G Robinson
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

5.  The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man.

Authors:  S C Jones; A Alavi; D Christman; I Montanez; A P Wolf; M Reivich
Journal:  J Nucl Med       Date:  1982-07       Impact factor: 10.057

6.  "Eight-drugs-in-one-day" chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas.

Authors:  J M Rozental; H I Robins; J Finlay; B Healey; A B Levin; R A Steeves; P C Kohler; H S Schutta; D L Trump
Journal:  Cancer       Date:  1989-06-15       Impact factor: 6.860

7.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography.

Authors:  G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

8.  In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas.

Authors:  C G Rhodes; R J Wise; J M Gibbs; R S Frackowiak; J Hatazawa; A J Palmer; D G Thomas; T Jones
Journal:  Ann Neurol       Date:  1983-12       Impact factor: 10.422

9.  Thalamic tumours invading the brain stem produce crossed cerebellar diaschisis demonstrated by PET.

Authors:  H Fukuyama; M Kameyama; K Harada; N Fujimoto; A Kobayashi; W Taki; T Ishikawa; H Handa; S Tanada; K Torizuka
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-05       Impact factor: 10.154

10.  Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors.

Authors:  G Di Chiro; R A Brooks; N J Patronas; D Bairamian; P L Kornblith; B H Smith; L Mansi; J Barker
Journal:  Ann Neurol       Date:  1984       Impact factor: 10.422

View more
  8 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

2.  Prediction of pathology and survival by FDG PET in gliomas.

Authors:  M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

3.  Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.

Authors:  A G Vlassenko; B Thiessen; B J Beattie; M G Malkin; R G Blasberg
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 4.  Prediction of brain tumor therapy response by PET.

Authors:  R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23.

Authors:  Corinne Beinat; Chirag B Patel; Yuanyang Xie; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

6.  Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers.

Authors:  Craig J Galbán; Mahaveer S Bhojani; Kuei C Lee; Charles R Meyer; Marcian E Van Dort; Kyle K Kuszpit; Robert A Koeppe; Rajesh Ranga; Bradford A Moffat; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

Review 7.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

8.  [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.

Authors:  Christian Pötzi; Alexander Becherer; Christine Marosi; Georgios Karanikas; Monika Szabo; Robert Dudczak; Kurt Kletter; Susanne Asenbaum
Journal:  J Neurooncol       Date:  2007-05-11       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.